FDA appropriations bill passes House
This article was originally published in The Rose Sheet
Executive Summary
The House on Aug. 2 passed its appropriations bill (H.R. 3161), which proposes $1.69 bil. in direct funding for FDA in fiscal 2008. No significant changes affecting FDA were made to the bill sent to the floor by the Agriculture Appropriations Subcommittee (1"The Rose Sheet" July 23, 2007, p. 8). The same day, Sen. Mike Enzi, R-Wyo., asked Majority Leader Harry Reid, D-N.V., to delay naming conferees for the legislation. "If we do this too early, we set ourselves up for the blame game, not for getting this key legislation done," Enzi said. The Senate has not yet passed its corresponding bill (S. 1859)...
You may also be interested in...
House, Senate Appropriations Committees More Than Match Request For FDA
House and Senate appropriators made certain in their recommendations for fiscal 2008 appropriations that FDA would be given opportunity to extend the scope of its oversight, with both houses of Congress more than matching the President's request
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.